Last reviewed · How we verify
NCT02411162
A Single Dose Phase I Exploratory Study in Healthy Volunteers With GSK2894512 Cream
Phase 1 trial testing Combination therapy GSK2894512 Cream A + GSK2894512 Cream B in Dermatitis, Atopic in 15 participants. Completed in 24 September 2015.
24 September 2015
Quick facts
| Lead sponsor | Stiefel, a GSK Company |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 15 |
| Start date | 7 July 2015 |
| Primary completion | 24 September 2015 |
| Estimated completion | 24 September 2015 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Combination therapy GSK2894512 Cream A + GSK2894512 Cream B — full drug profile →
- Combination therapy Vehicle Cream A + Vehicle Cream B — full drug profile →
Conditions studied
- Dermatitis, Atopic — all drugs for Dermatitis, Atopic →
Sponsor
Stiefel, a GSK Company — full company profile →
Who can join
Adults 18 to 45, male only, with Dermatitis, Atopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This will be an open-label, non-randomized, single-center study to assess the residency of GSK2894512 in the skin of healthy adult male volunteers with normal barrier function. The study will have two parts, Cohort 1 (Part A) followed by Cohort 2 (Part B). The study will assess the residence time in human skin . The primary objective is to evaluate the residency time in skin following topical application of two formulations of GSK2894512 Cream. The total study duration will be of 15 days including 1 to 7 days of treatment period, 8 to 14 days of post treatment period and 1 day of follow up. The screening period will be up to 28 days prior to Baseline (Day 1).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02411162
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dermatitis, Atopic
Currently open trials in the same condition.
- NCT07230860 — A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis · Phase 2 · recruiting
- NCT06899204 — Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate · recruiting
- NCT07042126 — Evaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
- NCT06881251 — A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) · Phase 2 · active not recruiting
- NCT06554847 — Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis · Phase 3 · active not recruiting
Other Stiefel, a GSK Company trials
Trials by the same sponsor.
- NCT02673619 — A Study to Evaluate Clinical Effect, Pharmacokinetics , Safety, and Tolerability of Umeclidinium in Palmar Hyperhidrosis · Phase 2 · completed
- NCT02014584 — Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia · Phase 3 · completed
- NCT01984775 — A Study to Evaluate the Irritation Potential of GSK2894512 Cream on Skin in Healthy Subjects · Phase 1 · completed
- NCT01446237 — U0289-405: An Open-Label, 12-Week Study to Evaluate the Efficacy and Safety of the Acne System (Benzoyl Peroxide 2.5%, S · NA · completed
- NCT01245140 — Efficacy of Alitretinoin Treatment in Patients With Pustular Form of Psoriasis · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02411162 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stiefel, a GSK Company
- Last refreshed: 9 May 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02411162.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing